The Home Depot (NYSE: HD) reported better-than-expected earnings for the third quarter of 2019 but revenues fell short of estimates. The stock fell over 4% in premarket hours on Tuesday.
Net sales of $27.2 billion rose 3.5% from the same period last year but came below consensus estimates of $27.5 billion. Comparable sales were positive 3.6% and comparable sales in the US were positive 3.8%.
Net earnings were $2.8 billion, or $2.53 per share, compared to $2.9 billion, or $2.51 per share, in the year-ago quarter, reflecting EPS growth of 0.8%.
Craig Menear, Chairman, CEO and President, stated, “Our third quarter results reflected broad-based growth across our business, yet sales were below our expectations driven by the timing of certain benefits associated with our One Home Depot strategic investments. We are largely on track with these investments and have seen positive results, but some of the benefits anticipated for fiscal 2019 will take longer to realize than our initial assumptions. As a result, today we are updating our fiscal 2019 sales guidance, and we are reaffirming our fiscal 2019 earnings-per-share guidance.”
During the quarter, the company recorded a 1.5% growth in customer transactions. Average ticket rose 1.9% while sales per square foot increased 3.5%.
The Home Depot updated its sales and comp sales guidance for fiscal 2019, a 52-week year compared to fiscal 2018, which was a 53-week year. The company now expects fiscal 2019 sales to grow approx. 1.8% and comp sales for the comparable 52-week period to increase approx. 3.5%, compared to the previous sales growth guidance of 2.3% and comp sales growth of 4%. Diluted EPS is expected to grow approx. 3.1% to $10.03 from 2018.
At the end of the third quarter, the company operated a total of 2,290 retail stores in all 50 states, the District of Columbia, Puerto Rico, US Virgin Islands, Guam, 10 Canadian provinces and Mexico.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
